Subscribe
Home
Issues
Latest Issue
Issue Archive
Special Issues
2022 Midyear Review: Non–Small-Cell Lung Cancer
2022 Oncology Biosimilar Guide to Patient Support Services
2022 Breast Cancer Guide to Patient Support Services
Browse By Topic
Practice Management
Financial Management
Reimbursement
Health Policy
Quality Care
ICD Codes
Survivorship
FDA Approvals, News & Updates
In the News
Guide to Patient Support Services
Index
Introduction
2023 Spotlight
Conference Correspondent
ASCO 2022 - Wrap Up
NSCLC IO 2022 - Midyear Review
SABCS 2021 Wrap-Up
Dual IO 2021 Year in Review
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Webinars
Rapid Reactions
In the News
Quick Quiz
Multiple Myeloma Monthly Minutes
Melanoma Monthly Minutes
Press Releases
Women's Health Monthly Minutes
Lung Cancer Monthly Minutes
Gastrointestinal Cancer Monthly Minutes
Issues
2021
October 2021, Vol 11, No 10
October 2021, Vol 11, No 10
Aspacytarabine Safe and Effective in Patients with AML Unfit for Intensive Chemotherapy
By
Charlie Dawson
Hematologic Malignancies
According to results from a clinical trial presented during the American Society of Clinical Oncology 2021 virtual annual meeting, aspacytarabine (BST-236), a prodrug of cytarabine, appears safe and effective as first-line therapy for patients with acute myeloid leukemia (AML) who are unfit for intensive chemotherapy.
Read More ›
Lisaftoclax, a Novel BCL-2 Inhibitor, Shows Promise in Relapsed or Refractory CLL and SLL
By
Patricia Stewart
Hematologic Malignancies
The novel BCL-2 inhibitor, lisaftoclax (APG-2575), elicited encouraging responses and acceptable tolerability in patients with relapsed or refractory chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and other hematologic malignancies, according to results of a phase 1 study presented at the American Society of Clinical Oncology 2021 virtual annual meeting.
Read More ›
Olaparib Prolongs Survival in Patients with Early-Stage Breast Cancer and BRCA Mutation
By
William King
Breast Cancer
The use of the PARP inhibitor olaparib (Lynparza) for 1 year after receiving standard chemotherapy in the neoadjuvant or the adjuvant setting significantly improved invasive disease-free survival in patients with high-risk, early-stage, HER2 negative breast cancer and BRCA1 or BRCA2 mutations, according to results presented at the American Society of Clinical Oncology 2021 virtual annual meeting.
Read More ›
The Impact of New Drug Compounding Standards on Your Practice
By
Dawn Holcombe, MBA, FACMPE, ACHE
From the Editor
On August 31, 2021, proposed revisions to the United States Pharmacopeia (USP) General Chapter 797 Pharmaceutical Compounding – Sterile Compounding (USP) were published. For several years, different versions of USP have fostered concern and confusion about whether these pharmacy standards apply to (and will impact) the drug preparation and handling that is an integral part of oncology medical practices, as well as other specialties.
Read More ›
Role of Radiology in Intrahepatic Cholangiocarcinoma Addressed at 2 Interventional Oncology and Radiology Meetings
Cholangiocarcinoma
Key topics related to intrahepatic cholangiocarcinoma (CCA) were presented at the 2021 Society of Interventional Oncology (SIO) and the Society of Interventional Radiology (SIR) meetings and were discussed at the CCA Summit. Bruno C. Odisio, MD, FSIR, Interventional Radiologist and Co-Director of Research, Interventional Radiology, M.D. Anderson Cancer Center, Houston, TX, reviewed the findings.
Read More ›
5-Year Follow-Up Study Confirms Safety and Efficacy of Trastuzumab Biosimilar in Patients with HER2-Positive Breast Cancer
By
William King
Biosimilars
During the virtual European Society for Medical Oncology Congress 2021, 5-year follow-up data from a clinial trial showed comparable results related to cardiac safety and long-term efficacy between trastuzumab (Herceptin) and the biosimilar trastuzumab-dttb (SB3; Ontruzant) in patients with HER2-positive, early or locally advanced breast cancer. These findings were reported in a poster presentation by Xavier Pivot, MD, PhD, General Director, Centre Paul Strauss, Institut de Cancérologie Strasbourg Europe, France, and colleagues.
Read More ›
Why Quality Documentation Matters
By
Jan Hailey, MHL, CMC, CMCO, CMIS, CMOM
Practice Management
Clinical documentation refers to the recording of pertinent facts, findings, and observations related to an individual’s health history, including past and present illnesses, examinations, tests, treatments, and outcomes. It plays a critical role in helping physicians and other medical professionals plan treatments, monitor a patient’s health status over time, and ensure continuity of care. It also facilitates accurate and timely claims review and payment, appropriate utilization review and quality-of-care evaluations, and collection of data that may be useful in research and education. As discussed in this article, quality documentation is essential for ensuring the well-being of your patients as well as your practice.
Read More ›
Select Ongoing Trials Currently Enrolling Patients with Multiple Myeloma
Clinical Trials Tracker
,
Multiple Myeloma
The following clinical trials represent a selection of key studies currently recruiting patients with multiple myeloma for inclusion in investigations of new therapies and new regimens of existing treatments for the disease. Each clinical trial description includes the NLM Identifier to be used as a reference with ClinicalTrials.gov. This information can help oncology practice managers and providers direct eligible patients to one of these clinical trials.
Read More ›
Adjuvant Nivolumab Prolongs Disease-Free Survival in Muscle-Invasive Urothelial Carcinoma
In the Literature
Nivolumab (Opdivo) has been shown to have antitumor activity in patients with metastatic urothelial carcinoma who received platinum treatment. However, the role of this agent as adjuvant therapy in high-risk muscle-invasive urothelial carcinoma following surgery has been unclear. In a recent study, researchers evaluated the efficacy and safety of adjuvant nivolumab compared with placebo in patients with muscle-invasive urothelial carcinoma following radical surgery (Bajorin DF, et al. N Engl J Med. 2021;384:2102-2104).
Read More ›
Exkivity Novel Oral Targeted Therapy Approved for Metastatic NSCLC with EGFR Exon 20 Insertion Mutations
FDA Approvals, News & Updates
,
Lung Cancer
On September 15, 2021, the FDA accelerated the approval of mobocertinib (Exkivity; Takeda), an oral kinase inhibitor, for adults with locally advanced or metastatic non–small-cell lung cancer (NSCLC) and EGFR exon 20 insertion mutations, as detected by an FDA-approved test, whose disease progressed during or after platinum-based chemotherapy. Mobocertinib received breakthrough therapy and orphan drug designations for this indication.
Read More ›
Page 1 of 2
1
2
View the Latest Issue of OPM
Read Issue
Top Trending Articles
1.
Specialty Carve-Outs: What Are the Implications for Patients and Practices?
By
Dawn Holcombe, MBA, FACMPE, ACHE
2.
New Policies Regarding Intravenous Iron Replacement Are Creating Conundrum for Providers and Payers
By
Dawn Holcombe, MBA, FACMPE, ACHE
3.
2023 Spotlight: Amgen
Home
Issues
Latest Issue
Issue Archive
Special Issues
2022 Midyear Review: Non–Small-Cell Lung Cancer
2022 Oncology Biosimilar Guide to Patient Support Services
2022 Breast Cancer Guide to Patient Support Services
Browse By Topic
Practice Management
Financial Management
Reimbursement
Health Policy
Quality Care
ICD Codes
Survivorship
FDA Approvals, News & Updates
In the News
Guide to Patient Support Services
Index
Introduction
2023 Spotlight
Conference Correspondent
ASCO 2022 - Wrap Up
NSCLC IO 2022 - Midyear Review
SABCS 2021 Wrap-Up
Dual IO 2021 Year in Review
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Webinars
Rapid Reactions
In the News
Quick Quiz
Multiple Myeloma Monthly Minutes
Melanoma Monthly Minutes
Press Releases
Women's Health Monthly Minutes
Lung Cancer Monthly Minutes
Gastrointestinal Cancer Monthly Minutes